Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eli Lilly Japan Aims at \100 Billion Sales in 2008: President Crenshaw
March 31, 2008
- JAPhMed to Take 1st Exam for Pharmaceutical Medicine
March 31, 2008
- Korosho to Start Chronic Kidney Disease Research Project in October
March 31, 2008
- JCROA to Introduce Monitor Certification System
March 31, 2008
- 174 More Hospitals to Be Designated as DPC Hospitals
March 31, 2008
- Usefulness of Tavocept Confirmed: ASKA
March 31, 2008
- Fees for 5 Standard Chemotherapy Regimens to Be Raised in April
March 31, 2008
- Need to Permanently Post Experts Stressed by Group Members
March 24, 2008
- Pfizer to Start 28 PIII Studies in Cancer, Diabetes, Pain
March 24, 2008
- SELF-MEDICATION NEWS IN BRIEF
March 24, 2008
- Novo Nordisk to Apply for Liraglutide in 2008: Mr Eilersen
March 24, 2008
- Lilly Terminates Development of Inhaled Insulin
March 24, 2008
- MEDICAL DEVICE NEWS IN BRIEF
March 24, 2008
- Zeria to Codevelop Remedy for FD with Astellas
March 24, 2008
- Herceptin Postoperative Adjuvant Chemotherapy Judged to Be Cost Effective
March 24, 2008
- Competitors' Exodus Gives Better Chance to NBI: Dr Nishikawa
March 24, 2008
- US Embassy, ACCJ Seminar Highlights Importance of Prevention
March 24, 2008
- Towa, Nichi-Iko to Hire More New Graduates
March 24, 2008
- Eisai Obtains Option Rights to M's Science's SA4503
March 24, 2008
- Pharmacists Are More Conservative than Doctors about the Use of Generics: CareNet Survey
March 24, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…